A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

  1. Cohn, A.L.
  2. Tabernero, J.
  3. Maurel, J.
  4. Nowara, E.
  5. Sastre, J.
  6. Chuah, B.Y.S.
  7. Kopp, M.V.
  8. Sakaeva, D.D.
  9. Mitchell, E.P.
  10. Dubey, S.
  11. Suzuki, S.
  12. Hei, Y.-J.
  13. Galimi, F.
  14. McCaffery, I.
  15. Pan, Y.
  16. Loberg, R.
  17. Cottrell, S.
  18. Choo, S.-P.
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2013

Alea: 24

Zenbakia: 7

Orrialdeak: 1777-1785

Mota: Artikulua

DOI: 10.1093/ANNONC/MDT057 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus